ArticleCureus2025
The New Kid on the Block: Validating the Role of Indocyanine Green for Sentinel Lymph Node Biopsy in the Post-neoadjuvant Setting in Patients With Breast Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective There is scarce literature on the role of indocyanine green (ICG) in sentinel lymph node biopsy (SLNB) post-neoadjuvant chemotherapy (NACT) in breast cancer patients, specifically in the Indian population. This study aimed to address this gap by evaluating the identification rates and accuracy of SLNB using ICG. Methods A prospective observational study was conducted over 18 months at Vardhman Mahavir Medical College, New Delhi, involving 30 patients with locally advanced breast cancer. The primary objectives were identification rates, positive predictive value, and false negatives. All patients underwent SLNB post-NACT and, irrespective of SLNB results, underwent axillary lymph node dissection (ALND). The secondary objectives of the study focused on complications related to ICG dye. Results The mean age of the cohort was 44.83 years. The SLNB technique using ICG showed an identification rate of 100% with a sensitivity of 91.67%, a specificity of 100% with a false negative rate of 5.55%, and an accuracy of 96.67%. No cases of allergic reactions to ICG or skin necrosis were observed. Conclusions Our findings validate the use of ICG dye for SLNB in neoadjuvant setting for patients with breast cancer, demonstrating high sensitivity and specificity. ICG fluorescence imaging permits real-time visualization of lymphatics for SLNB and, at the same time, minimizes complications and high-tech nuclear medicine infrastructure requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.